FDA Approved Products

Application #TypeSponsorNotesProduct #Drug NameFormStrengthActive IngredientApproval DateMarketing StatusReference Standard
218944NDASYNDAX001REVUFORJTABLET;ORALEQ 25MG BASEREVUMENIB CITRATE2024-11-15PrescriptionNo
002REVUFORJTABLET;ORALEQ 110MG BASEREVUMENIB CITRATE2024-11-15PrescriptionNo
003REVUFORJTABLET;ORALEQ 160MG BASEREVUMENIB CITRATE2024-11-15PrescriptionYes